<DOC>
	<DOC>NCT00638326</DOC>
	<brief_summary>The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel after elective percutaneous coronary intervention.</brief_summary>
	<brief_title>Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity</brief_title>
	<detailed_description />
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Clopidogrelna√Øve stable angina pectoris (CCS IIII) Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter stenosis greater than 50% in two independent projections) feasible for ad hoc stent implantation Acute coronary syndrome (STEMI, NSTEMI or unstable angina) Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks Contraindication to antiplatelet therapy Significant LM stenosis PCI due to instent restenosis Lesion located in bypass grafts Stroke in past one year Reduced life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Clopidogrel, thrombosis, Percutaneous Transluminal Coronary Angioplasty, stents</keyword>
</DOC>